For comments, suggestions
Created with Raphaël 2.1.0 10.10.2014 Opening of the national phase 11.12.2014 Preliminary and substantive examination 28.02.2015 Publication of the PCT application (A2) 31.07.2017 Publication of the decision of grant (B1) 31.01.2018 Completion of the opposition filing period 28.02.2018 Issuance of patent (C1) 18.05.2024 11.03.2025 Valid until 11.03.2026 Payment of maintenance fee 11.03.2033 Patent expiration date

Patent in force


(11)Number of the document4496
(21)Number of the applicationa 2014 0112
(22)Filing date of the application2013.03.11
 Date of filing the request for examination (de fond) 07.04.2017
(71)Name(s) of applicant(s), code of the countryGILEAD SCIENCES, INC., US;
(72)Name(s) of inventor(s), code of the countryCLARKE Michael O'Neil Hanrahan, US;
(73)Name(s) of owner(s), code of the countryGILEAD SCIENCES, INC., US;
(54)Title of the invention2'-Substituted carba-nucleoside analogs for antiviral treatment  
(13)Kind-of-document code
C1, BOPI 02/2018
B1, BOPI 07/2017
A2, BOPI 02/2015
(51)International Patent Classification C07H 19/23 (2006.01); A61K 31/706 (2006.01); A61P 31/16 (2006.01);
(19)CountryUS
(41)Date of publication of the application2015.02.28
(45)Date of publication of patent granting decision:2017.07.31
(47)Date of issuance of patent2018.02.28
(30)Priority61/610411, 2012.03.13, US
(74)Patent attorneyMARGINE Ion, Str. Lomonosov nr. 43, ap. 23, MD-2009, Chişinău, Republica Moldova
 Substantive examiner(s)JOVMIR Tudor
(85)Date of introducing the national procedure2014.10.10
(86)International applicationPCT/US2013/030196, 2013.03.11
(87)International publicationWO 2013/138236 A1, 2013.09.19
 Payment for maintenance up to the date2025.03.11
Up
/inventions/details/a 2014 0112